All right... time for a reality check.
The reasons I don't think offering sunifiram would be a good idea:
1. It is no doubt patented, and since it is a new pharmaceutical, there is a high likelihood that any company that tries to sell it would get sued ASAP.
2. Potency does not necessarily correlate with maximal activity. Racetam nootropics tend to have bell-shaped dose-response curves. So the question you want answered is not how potent a compound is, but how strong the effect is at the dose which has the maximal effect. For example, some steroids that are considerably more potent on an mg per mg basis are much less desirable in terms of effects. Accordingly, here is a quote from one of the sunifiram studies:
The maximal antiamnesic effect of DM235 was obtained with the dose of 0.001 mg kg–1 i.p. and maintained up to 0.1 mg kg–1 i.p. The DM235-induced antiamnesic effect was of the
same intensity as that exerted by the well-known nootropic drugs
piracetam (30 mg kg–1 i.p.), aniracetam (100 mg kg–1 p.o.) or rolipram (30 mg kg–1 p.o.) (Fig. 2A and
.
3. There are no human studies on this compound. So we know nothing about the toxicity, side effects, or pharmacokinetics in humans. I agree that it is promising, but self-experimentation with drugs like this - especially ones with an active dose of 1 mcg/kg - is dangerous. Not only that, but with a bell-shaped dose response curve, you have to hit a very narrow dosage range to achieve an effect, which is much more difficult if the doses are miniscule. It is possible that even a fraction of a milligram too much could make it so it had no nootropic effect at all.
Sunifiram, Potent Nootropics
